Ambys’ CSO, Michael Holmes, Included in 2020 List of Highly Cited Researchers
Ambys Medicines’ Chief Scientific Officer, Michael Holmes, Ph.D., was named to the 2020 list of Highly Cited Researchers, a distinction that ranks his publications in the top 1% of citations in the cross-field category. The Highly Cited Researchers list from Clarivate identifies scientists and social scientists who have demonstrated significant and broad influence, reflected in the publication of multiple papers frequently cited by their peers during the last decade.
This “who’s who” list of researchers draws on data an analysis of highly cited papers from 2009 to 2020. The result is an elite list of distinguished researchers that are pioneers in their fields…disproportionately contributing to extending the frontiers of knowledge and advancing innovation.
In 2018, Clarivate introduced a new, cross-field category to identify researchers with substantial influence across several fields. In 2020, nearly 2,500 researchers with cross-field impact were selected. For a second year in a row, Michael has been named to the cross-field list, primarily for his extensive published research in the field of genome editing.
“It’s an honor to be recognized for my contributions to the genome editing field and the pioneering application of this powerful technology in advancing basic science research, drug development, and the generation of new genomic medicines. These groundbreaking medicines have the potential to provide transformative, curative therapies for patients with significant unmet medical needs.”
Prior to joining Ambys, Michael spent nearly two decades breaking new ground with the use of zinc finger nucleases for genome editing in transformed and primary human cells, including hematopoietic stem cells, and tissues. “Genome editing was still a dream when we started”, Michael said. Since then, he has authored over 60 publications in the field of genome editing and gene regulation, as well as numerous patents. The result: multiple gene and cell therapies entering clinical development spanning diseases of the liver, hematopoietic system, immune system, and CNS.
Michael continues to forge new frontiers in liver regeneration at Ambys. “Taking cell and gene therapy to the next level in a space completely new and different attracted me to Ambys,” Michael added “I am inspired by the mission to develop novel therapies for patients with severe liver diseases. By leveraging the incredible potential of cell and gene therapies to modify disease biology, harness the regenerative power of the liver, and restore function, we have the opportunity to provide durable and potentially curative therapies to patients with so few options.”
“Despite the growing epidemic of liver disease in the US and around the world, advances have been slow to materialize.” said Jeff Tong, Ph.D., Interim CEO and Executive Chairman of the Board at Ambys. “Applying cell and gene therapies in a novel way has the potential to dramatically change this course. We are fortunate to have someone of Michael’s caliber leading our scientific efforts in regenerative medicine.”